Overview
Robotic surgery technology firm's Q1 revenue rose 23%, beating analyst expectations
Adjusted EPS for Q1 beat analyst expectations
Company repurchased 2.3 mln shares for $1.1 bln in Q1
Outlook
Company expects 2026 da Vinci procedure growth of 13.5% to 15.5%
Intuitive Surgical sees 2026 non-GAAP gross profit margin of 67.5% to 68.5%
Company expects 2026 non-GAAP operating expense growth of 11% to 14%
Result Drivers
PROCEDURE VOLUME - Growth in worldwide procedure volumes, including 16% growth for da Vinci and 39% for Ion, drove higher revenue
SYSTEM PLACEMENTS - Increased placements of da Vinci surgical systems, especially da Vinci 5, contributed to higher systems revenue
INSTALLED BASE EXPANSION - Growth in the installed base of da Vinci and Ion systems supported increased recurring revenue from instruments, accessories, and services
Company press release: ID:nGNX1HSx1K
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$2.77 bln
$2.61 bln (24 Analysts)
Q1 Adjusted EPS
Beat
$2.50
$2.10 (23 Analysts)
Q1 EPS
$2.28
Q1 Adjusted Net Income
Beat
$901.1 mln
$757.13 mln (20 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Intuitive Surgical Inc is $609.00, about 30.8% above its April 20 closing price of $465.60
The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 59 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)